What You Should Know:
- QuantHealth has launched LRDM v1.0, the world’s first clinical trial foundation model that simulates patient outcomes using data from over 100 million individuals and billions of clinical datapoints.
- This technology marks a pivotal shift by applying large-scale AI modeling to clinical trial design—where 90% of drug candidates fail—offering the potential to cut waste, reduce timelines, and improve success rates
QuantHealth Unveils First-Ever Clinical Trial Foundation Model to Revolutionize Trial Design and Drug Success Rates
QuantHealth, a leader in AI-powered clinical trial simulation, has introduced the Large Real-World Drug Model (LRDM v1.0)—a first-of-its-kind foundation model capable of simulating clinical trials using vast, real-world datasets. Unlike existing AI tools that focus primarily on drug discovery, LRDM v1.0 addresses the clinical stage of drug development, a phase that consumes over half of all development budgets and sees a 90% failure rate.
QuantHealth’s LRDM v1.0 is powered by an end-to-end transformer architecture capable of processing over 100 million patient records and billions of therapeutic datapoints. It enables high-fidelity simulations to accurately predict patient response to treatment across entire trials. The model supports critical decisions such as go/no-go evaluations, cohort optimization, and drug repurposing.
Built on a proprietary AI engine trained with data from 350 million patients and 5 million mechanistic variables, LRDM v1.0 delivers high-precision insights. This simulation capability empowers sponsors to design precision trials, accelerate patient accrual, reduce costly failures, and shorten timelines from molecule to market.
“Healthcare generates nearly 30% of the world’s data—about 138 billion gigabytes per day—but leveraging this at scale for actionable insight has been a monumental challenge,” said Orr Inbar, CEO and Co-Founder of QuantHealth. “We’ve invested over $10 million in R&D over four years to overcome this barrier through systems biology, novel AI architectures, and high-performance computing. LRDM v1.0 is the result.”
QuantHealth currently supports dozens of trials annually, working with 8 of the top 20 pharma companies across multiple modalities—including biologics, small molecules, and cell and gene therapies—in therapeutic areas such as oncology, cardiovascular, and autoimmune diseases.
The company’s solutions are available through self-service simulation workflows, model APIs, and will soon be accessible via the AWS Marketplace.
